Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Companies	$6.02 +9.2%	$4.85	$3.96 ▼ $9.85	$2.23B	0.28	2.61 million shs	11.49 million shs
BHVN Biohaven	$15.43 -1.1%	$18.21	$14.33 ▼ $55.70	$1.58B	0.95	1.27 million shs	1.36 million shs
FLXN Flexion Therapeutics	$9.12	$9.20	$4.30 ▼ $13.66	$458.93M	1.53	1.18 million shs	N/A
IRON Disc Medicine	$53.71 +1.9%	$45.86	$30.82 ▼ $68.73	$1.86B	0.73	352,007 shs	705,215 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Companies	+8.57%	+26.63%	+31.62%	-15.82%	-4.75%
BHVN Biohaven	-1.05%	-9.21%	-20.93%	-47.25%	-54.32%
FLXN Flexion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IRON Disc Medicine	+1.90%	+7.38%	+17.45%	+5.27%	+38.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Companies	3.9887 of 5 stars	1.9	2.0	0.0	4.0	3.1	3.3	1.9
BHVN Biohaven	2.9903 of 5 stars	4.5	1.0	0.0	0.0	1.8	2.5	0.6
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	2.1709 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Companies	1.86	Reduce	$7.42	23.30% Upside
BHVN Biohaven	3.07	Buy	$59.46	285.46% Upside
FLXN Flexion Therapeutics	0.00	N/A	N/A	N/A
IRON Disc Medicine	3.09	Buy	$96.70	80.04% Upside

Current Analyst Ratings Breakdown

Latest FLXN, IRON, BHC, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	IRON Disc Medicine	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
5/19/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
5/2/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/28/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $57.00
4/24/2025	BHVN Biohaven	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/7/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$9.00 ➝ $8.50
3/20/2025	BHVN Biohaven	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00
3/18/2025	IRON Disc Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$99.00 ➝ $132.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Companies	$9.73B	0.23	$6.40 per share	0.94	($0.89) per share	-6.76
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
FLXN Flexion Therapeutics	$85.55M	5.36	N/A	N/A	($0.34) per share	-26.82
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Companies	-$46M	-$0.11	N/A	1.29	0.37	-0.48%	-577.82%	5.24%	7/30/2025 (Estimated)
BHVN Biohaven	-$408.17M	-$9.36	N/A	N/A	N/A	N/A	-225.12%	-158.89%	8/5/2025 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
IRON Disc Medicine	-$76.43M	-$3.92	N/A	N/A	N/A	N/A	-25.24%	-23.96%	8/6/2025 (Estimated)

Latest FLXN, IRON, BHC, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Companies	N/A	0.86	0.62
BHVN Biohaven	N/A	2.89	2.89
FLXN Flexion Therapeutics	N/A	4.38	4.05
IRON Disc Medicine	N/A	19.36	19.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Companies	78.65%
BHVN Biohaven	88.78%
FLXN Flexion Therapeutics	90.01%
IRON Disc Medicine	83.70%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Companies	8.05%
BHVN Biohaven	16.00%
FLXN Flexion Therapeutics	9.13%
IRON Disc Medicine	4.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Companies	19,900	370.08 million	338.06 million	Optionable
BHVN Biohaven	239	102.11 million	84.94 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	Optionable
IRON Disc Medicine	30	34.63 million	28.50 million	Not Optionable

FLXN, IRON, BHC, and BHVN Headlines

Recent News About These Companies

Disc Medicine (NASDAQ:IRON) Coverage Initiated at Raymond James

June 13 at 2:38 AM | americanbankingnews.com

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

June 12 at 7:30 AM | globenewswire.com

Cantor Fitzgerald Comments on Disc Medicine FY2026 Earnings

June 12 at 2:49 AM | americanbankingnews.com

Disc Medicine (NASDAQ:IRON) Coverage Initiated by Analysts at Raymond James

June 11 at 10:18 AM | marketbeat.com

Cantor Fitzgerald Forecasts Disc Medicine FY2026 Earnings

June 10, 2025 | marketbeat.com

Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 2,996 Shares of Stock

June 10, 2025 | insidertrades.com

William Jacob Savage Sells 2,996 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

June 9, 2025 | marketbeat.com

Millennium Management LLC Buys Shares of 7,879 Disc Medicine, Inc. (NASDAQ:IRON)

June 9, 2025 | marketbeat.com

Ameriprise Financial Inc. Invests $335,000 in Disc Medicine, Inc. (NASDAQ:IRON)

June 6, 2025 | marketbeat.com

Disc Medicine, Inc. (NASDAQ:IRON) Receives $98.80 Average Price Target from Brokerages

June 6, 2025 | americanbankingnews.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 74,454 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

June 3, 2025 | marketbeat.com

Bank of America Corp DE Reduces Position in Disc Medicine, Inc. (NASDAQ:IRON)

June 3, 2025 | marketbeat.com

Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Buy" from Analysts

June 3, 2025 | marketbeat.com

Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Nuveen Asset Management LLC

June 2, 2025 | marketbeat.com

Wellington Management Group LLP Sells 444,821 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

May 30, 2025 | marketbeat.com

Disc Medicine to Participate in Upcoming Investor Conferences

May 28, 2025 | globenewswire.com

Disc Medicine, Inc. (NASDAQ:IRON) Stock Position Raised by Deutsche Bank AG

May 28, 2025 | marketbeat.com

Point72 Asset Management L.P. Sells 742,423 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

May 25, 2025 | marketbeat.com

Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 6,677 Shares of Stock

May 23, 2025 | insidertrades.com

Woodline Partners LP Boosts Stake in Disc Medicine, Inc. (NASDAQ:IRON)

May 23, 2025 | marketbeat.com

Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Rafferty Asset Management LLC

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLXN, IRON, BHC, and BHVN Company Descriptions

Bausch Health Companies NYSE:BHC

$6.02 +0.51 (+9.17%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$6.02 +0.01 (+0.17%)

As of 06/13/2025 07:59 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Biohaven NYSE:BHVN

$15.43 -0.16 (-1.05%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$15.44 +0.01 (+0.06%)

As of 06/13/2025 06:55 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Disc Medicine NASDAQ:IRON

$53.71 +1.00 (+1.90%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$55.65 +1.94 (+3.61%)

As of 06/13/2025 05:54 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time